Issue Date: January 29, 2007
Coley halts work on hepatitis drug
Massachusetts-based Coley Pharmaceutical will discontinue development of Actilon, its candidate for the treatment of hepatitis C virus infection, due to disappointing results from two concurrent clinical trials. In dropping the program, Coley says it has reduced its workforce, primarily drug development staff, by approximately 22%, or 33 employees, and that it will seek to outsource drug development activities going forward.
- Chemical & Engineering News
- ISSN 0009-2347
- Copyright © American Chemical Society